IL133397A - Pharmaceutical compositions for oral administration comprising an active substance and a cyclodextrin - Google Patents

Pharmaceutical compositions for oral administration comprising an active substance and a cyclodextrin

Info

Publication number
IL133397A
IL133397A IL13339798A IL13339798A IL133397A IL 133397 A IL133397 A IL 133397A IL 13339798 A IL13339798 A IL 13339798A IL 13339798 A IL13339798 A IL 13339798A IL 133397 A IL133397 A IL 133397A
Authority
IL
Israel
Prior art keywords
cyclodextrin
pharmaceutical compositions
oral administration
active substance
family
Prior art date
Application number
IL13339798A
Other languages
English (en)
Other versions
IL133397A0 (en
Original Assignee
Ucb Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=3890611&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL133397(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ucb Sa filed Critical Ucb Sa
Publication of IL133397A0 publication Critical patent/IL133397A0/xx
Publication of IL133397A publication Critical patent/IL133397A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nanotechnology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Physiology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Nutrition Science (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pulmonology (AREA)
  • Zoology (AREA)
  • Anesthesiology (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL13339798A 1997-07-03 1998-07-02 Pharmaceutical compositions for oral administration comprising an active substance and a cyclodextrin IL133397A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
BE9700572A BE1011251A3 (fr) 1997-07-03 1997-07-03 Compositions pharmaceutiques administrables par voie orale, comprenant une substance active et une cyclodextrine.
PCT/BE1998/000100 WO1999001133A1 (fr) 1997-07-03 1998-07-02 Compositions pharmaceutiques administrables par voie orale, comprenant une substance active et une cyclodextrine

Publications (2)

Publication Number Publication Date
IL133397A0 IL133397A0 (en) 2001-04-30
IL133397A true IL133397A (en) 2005-07-25

Family

ID=3890611

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13339798A IL133397A (en) 1997-07-03 1998-07-02 Pharmaceutical compositions for oral administration comprising an active substance and a cyclodextrin

Country Status (20)

Country Link
US (1) US6455533B1 (de)
EP (1) EP0994710B2 (de)
JP (2) JP2002508773A (de)
KR (1) KR100551510B1 (de)
CN (1) CN1150900C (de)
AT (1) ATE224717T1 (de)
AU (1) AU727140B2 (de)
BE (1) BE1011251A3 (de)
BR (1) BR9810495A (de)
CA (1) CA2294783C (de)
DE (1) DE69808297T3 (de)
DK (1) DK0994710T4 (de)
ES (1) ES2184293T5 (de)
ID (1) ID23806A (de)
IL (1) IL133397A (de)
NZ (1) NZ501820A (de)
PL (1) PL192348B1 (de)
PT (1) PT994710E (de)
RU (1) RU2192863C2 (de)
WO (1) WO1999001133A1 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0028575D0 (en) * 2000-11-23 2001-01-10 Elan Corp Plc Oral pharmaceutical compositions containing cyclodextrins
CA2437375A1 (en) * 2001-02-05 2002-08-15 R.P. Scherer Technologies, Inc. Methods and compositions for reducing the taste of pharmaceutically active agents
ES2354688T3 (es) * 2002-01-15 2011-03-17 Ucb Farchim S.A. Formulaciones para la administración oral de compuestos activos.
ES2298540T3 (es) * 2002-04-04 2008-05-16 Pfizer Products Inc. Comprimido masticable agradable.
CA2574602A1 (en) * 2004-07-22 2006-02-02 Pfizer Products Inc. Taste masking formulation comprising the drug in a dissolution-retarded form and/or cyclodextrin in a dissolution-enhanced form
US20060147518A1 (en) * 2004-12-30 2006-07-06 Pierre Fabre Medicament Stable solid dispersion of a derivative of vinca alkaloid and process for manufacturing it
US20060198885A1 (en) * 2005-02-22 2006-09-07 Sun Pharmaceutical Industries Ltd. Oral pharmaceutical composition
US20070086974A1 (en) * 2005-10-06 2007-04-19 Gawande Rahul S Cetirizine compositions
WO2007144902A1 (en) * 2006-06-12 2007-12-21 Jubliant Organosys Limited Chewable bilayer tablet formulation
JP2008143807A (ja) * 2006-12-07 2008-06-26 Sato Pharmaceutical Co Ltd 感冒薬カプセル剤及びその製造方法
EP2178522A1 (de) * 2007-07-11 2010-04-28 Fertin Pharma A/S Komprimierte kaugummitablette mit einem geschmacksmaskierenden mittel
EP2178521B1 (de) * 2007-07-11 2014-01-15 Fertin Pharma A/S Stabiles arzneimittelhaltiges kaugummi mit einem cyclodextrin-einschlusskomplex
WO2009054432A1 (ja) * 2007-10-26 2009-04-30 Daiichi Sankyo Company, Limited 口腔内速崩壊性医薬組成物およびその製造方法
US8138192B2 (en) * 2007-10-31 2012-03-20 Genebiology, Inc. Injectable meclizine formulations and methods
US20090137606A1 (en) * 2007-11-06 2009-05-28 Rakefet Cohen Chewable formulations
CN102143737A (zh) * 2008-09-05 2011-08-03 麦克内尔-Ppc股份有限公司 制备西替利嗪片剂的方法
CA2771403C (en) 2009-08-19 2015-02-24 Eisai R&D Management Co. Ltd. Quinoline derivative-containing pharmaceutical composition
WO2011110939A2 (en) 2010-03-11 2011-09-15 Rubicon Research Private Limited Pharmaceutical compositions of substituted benzhydrylpiperazines
WO2011150859A1 (en) * 2010-06-04 2011-12-08 Comprehensive Drug Enterprises Ltd Oral meclizine aqueous formulations with taste flavoring agent
CN101905027A (zh) * 2010-07-27 2010-12-08 北京华禧联合科技发展有限公司 含米格列奈钙和环糊精的口服药用组合物
WO2012037117A1 (en) 2010-09-13 2012-03-22 Bev-Rx, Inc. Aqueous drug delivery system comprising off - flavor masking agent
JP6038128B2 (ja) 2011-06-03 2016-12-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 レンバチニブ化合物に対する甲状腺癌対象及び腎臓癌対象の反応性を予測及び評価するためのバイオマーカー
RU2589833C2 (ru) * 2013-12-12 2016-07-10 Общество С Ограниченной Ответственностью "Фарма Старт" Твердая лекарственная форма препарата седативного и снотворного действия
KR102445606B1 (ko) * 2014-03-27 2022-09-20 유씨비 파쉼 소시에떼아노님 레보세티리진을 포함하는 약학 조성물
EP3187491A4 (de) 2014-08-28 2018-08-01 Eisai R&D Management Co., Ltd. Hochreines chinolinderivat und verfahren zur herstellung davon
US20180028662A1 (en) 2015-02-25 2018-02-01 Eisai R&D Management Co., Ltd. Method for Suppressing Bitterness of Quinoline Derivative
KR20240064733A (ko) 2015-03-04 2024-05-13 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
CA2988707C (en) 2015-06-16 2023-10-10 Eisai R&D Management Co., Ltd. Combination of cbp/catenin inhibitor and immune checkpoint inhibitor for treating cancer
CN108135894B (zh) 2015-08-20 2021-02-19 卫材R&D管理有限公司 肿瘤治疗剂
CN110072528B (zh) 2017-02-08 2022-04-26 卫材R&D管理有限公司 治疗肿瘤的药物组合物
WO2018212202A1 (en) 2017-05-16 2018-11-22 Eisai R&D Management Co., Ltd. Treatment of hepatocellular carcinoma
KR102110304B1 (ko) * 2017-06-30 2020-05-14 한미약품 주식회사 레보세티리진 및 몬테루카스트를 포함하는 안정성 및 복약순응도가 향상된 복합 츄어블정 및 그 제조방법
US20210236430A1 (en) * 2020-02-03 2021-08-05 Johnson & Johnson Consumer Inc. Single layer chewable tablet comprising cetirizine
ES3058094T3 (en) 2020-11-18 2026-03-06 Biopharma Synergies S L Orodispersible powder composition comprising an antihistamine compound

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO155805C (no) * 1981-02-06 1987-06-10 Ucb Sa Analogifremgangsmaate for fremstilling av terapeutisk virksomme 2-(4-(difenylmethyl)-1-piperazinyl)-eddiksyrer og deres amider og ikke-toksiske salter.
JPS58177949A (ja) * 1982-04-12 1983-10-18 Takeda Chem Ind Ltd ランカシジン群抗生物質包接化合物
JPS60204712A (ja) * 1984-03-29 1985-10-16 Ss Pharmaceut Co Ltd 塩酸メクリジンの安定化液状組成物
JPS63243031A (ja) † 1987-03-28 1988-10-07 Tokyo Tanabe Co Ltd 胆汁酸の固形製剤
US5206025A (en) * 1989-05-24 1993-04-27 Rhone-Poulenc Sante Porous pharmaceutical form and its preparation
FR2647343B1 (fr) 1989-05-24 1994-05-06 Rhone Poulenc Sante Nouvelle forme pharmaceutique poreuse et sa preparation
DE10199031I2 (de) † 1992-09-24 2004-09-23 Sepracor Inc Verwendung von (-) Cetrizin zur Behandlung allergischer Rhinitis und Asthma.
TW401300B (en) * 1992-12-25 2000-08-11 Senju Pharma Co Antiallergic composition for ophthalmic or nasal use
SI0731801T1 (en) * 1993-12-01 2002-06-30 Byk Gulden Lomberg Chemische Fabrik Gmbh Substituted aminoalkylaminopyridines
US5866179A (en) 1996-05-03 1999-02-02 Avant-Garde Technologies & Products S.A. Medicated chewing gum and a process for preparation thereof
GB0028575D0 (en) * 2000-11-23 2001-01-10 Elan Corp Plc Oral pharmaceutical compositions containing cyclodextrins
CA2574602A1 (en) * 2004-07-22 2006-02-02 Pfizer Products Inc. Taste masking formulation comprising the drug in a dissolution-retarded form and/or cyclodextrin in a dissolution-enhanced form

Also Published As

Publication number Publication date
EP0994710B1 (de) 2002-09-25
EP0994710A1 (de) 2000-04-26
HK1029060A1 (en) 2001-03-23
DK0994710T4 (da) 2005-10-17
PT994710E (pt) 2003-02-28
RU2192863C2 (ru) 2002-11-20
BR9810495A (pt) 2000-09-12
PL192348B1 (pl) 2006-10-31
ATE224717T1 (de) 2002-10-15
JP2007091760A (ja) 2007-04-12
WO1999001133A1 (fr) 1999-01-14
EP0994710B2 (de) 2005-09-21
KR20010014398A (ko) 2001-02-26
CA2294783C (fr) 2006-11-14
DE69808297T2 (de) 2003-04-17
ES2184293T5 (es) 2006-01-16
US20020032217A1 (en) 2002-03-14
BE1011251A3 (fr) 1999-06-01
AU727140B2 (en) 2000-12-07
DE69808297T3 (de) 2006-01-19
ID23806A (id) 2000-05-11
CA2294783A1 (fr) 1999-01-14
DE69808297D1 (de) 2002-10-31
KR100551510B1 (ko) 2006-02-13
IL133397A0 (en) 2001-04-30
CN1261799A (zh) 2000-08-02
US6455533B1 (en) 2002-09-24
AU8201598A (en) 1999-01-25
PL337794A1 (en) 2000-09-11
ES2184293T3 (es) 2003-04-01
NZ501820A (en) 2000-10-27
CN1150900C (zh) 2004-05-26
DK0994710T3 (da) 2003-01-20
JP2002508773A (ja) 2002-03-19

Similar Documents

Publication Publication Date Title
IL133397A0 (en) Pharmaceutical compositions for oral administration, comprising an active substance and a cyclodextrin
IL136285A0 (en) Pharmaceutical compositions containing an acid-labile active component
BG106030A (en) Pharmaceutical composition
MY118151A (en) Pharmaceutical formulations containing voriconazole.
PL347671A1 (en) Compounds and compositions for delivering active agents
BR0015188A (pt) Composições farmacêuticas
GEP20053473B (en) High Potency Dihydroergotamine Compositions
AU2274201A (en) Compounds and compositions for delivering active agents
AU2845599A (en) Pharmaceutical compositions and their use
IL141762A0 (en) New oral formulations
FI973828A0 (fi) Yhdisteitä ja koostumuksia aktiivisten aineiden annostelemiseksi
ZA200308221B (en) Pharmaceutical compositions for oral and topical administration.
ATE287264T1 (de) Oral anzuwendende buprenorphinhaltige arzneimittel
PL346764A1 (en) New oral formulation for 5-ht4
PL348419A1 (en) Sustained-release pharmaceutical preparation containing tilidine mesylate as active ingredient
CA2348474A1 (en) Pharmaceutically active composition and dispensing device
AU3580995A (en) Derivatives of carbohydrates and compositions containing them
EP1273301A3 (de) Pharmazeutische Zubereitungen, Wirkstoffe enthaltend, die sich für unerlaubte Verabreichung bieten
GEP20043377B (en) Pharmaceutical Complex
MD1473F2 (en) Antiherpetic remedy
AU2502301A (en) Medicament and combination of compatible medicaments
IL142112A0 (en) Pharmaceutical compositions based on alpha-cyclodextrin for the oral administration of lh-rh analogues
TW429144B (en) The pharmaceutical composition comprising the Con.A-Maltose complex and vehicle for oral use
ECSP941154A (es) Procedimiento para preparar una composicion farmaceutica a base de ciclosporina
MY152490A (en) New oral formulation

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees